UNITED STATES SECURITIES AND EXCHANGE COMMISSION

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

~~PURSUANT~~Date TOof ~~SECTION 13~~Report ~~OR 15~~(dDate of earliest event reported): January OF14, ~~THE~~2013

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 3, 2013

Callisto Pharmaceuticals, Inc.

(Exact name of Registrant as specified in its charter)

Delaware		001-32325		33-3894575
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

420 Lexington Avenue, Suite 1609 New York, NY		10170
(Address of principal executive offices)		(Zip code)

(212) 297-0010

(Registrant’s telephone number including area code)

N/A

(Former name and former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

x o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item~~ITEM 85.0107 ~~Other~~SUBMISSION ~~Events~~OF MATTERS TO A VOTE OF SECURITY HOLDERS

OnThe ~~January 3,~~reconvened ~~2013,~~Special Meeting of Stockholders of Callisto Pharmaceuticals, Inc. ( “Callisto”), ~~commenced~~was ~~its~~held ~~Special~~on ~~Meeting~~January 14, of2013. At ~~Stockholders~~the ~~as previously scheduled and adjourned its~~ Special Meeting of Stockholders, ~~until~~the ~~Monday,~~stockholders ~~January 14,~~of ~~2013~~Callisto atapproved ~~1:00 p.m.,~~and ~~Eastern~~adopted ~~Standard~~the ~~Time. The~~Agreement ~~Special~~and ~~Meeting~~Plan of ~~Stockholders~~Merger ~~was~~dated ~~adjourned~~as inof ~~order~~July 20, to2012, ~~provide~~as ~~stockholders~~amended ~~reasonable~~on ~~time~~October 15, to2012, ~~consider~~by ~~the~~and ~~recent~~between ~~announcement~~Callisto byand Synergy Pharmaceuticals Inc. (“Synergy”), ofpursuant ~~the~~to ~~results~~which ofCallisto ~~its~~will ~~Phase~~merge ~~IIb/III~~with ~~clinical~~and ~~trial.~~into Synergy, based on the votes listed below:

The reconvened Special Meeting of Stockholders will be held at Callisto’s offices at 420 Lexington Avenue, Suite 1609, New York, New York 10170. Stockholders who have already voted do not need to recast their votes. Proxies previously submitted in respect of the meeting will be voted at the adjourned meeting unless properly revoked. Given the adjournment, proxies may now be received by our registrar and transfer agent, Philadelphia Stock Transfer Inc., no later than January 13, 2013 at 11:59 p.m. (Eastern Standard Time).

For		Withheld/Against		Abstain		Broker Non- Votes
103,640,681		136,141		29,120		0

A copy of the press release announcing the results of the Special Meeting is attached hereto as exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

The following ~~exhibits~~exhibit ~~are~~is furnished as part of this Current Report on Form 8-K:

(d) Exhibits.

99.1 Press Release dated January 315, 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CALLISTO PHARMACEUTICALS, INC.
Date: January 3, 2013	By:	/s/ Gary S. Jacob
Date: January 15, 2013	By:	/s/ Gary S. Jacob
		Name: Gary S. Jacob, PhD
		Title: Chief Executive Officer

Filing Compare · CALLISTO PHARMACEUTICALS INC